Treatment is primarily by corticosteroids and immunosuppressive medications like cyclophosphamide, methotrexate, and azathioprine. DMARDs commonly in use are antimalarials such as hydroxychloroquine and immunosuppressants (e.g. methotrexate and azathioprine). Less toxic immunosuppressing medications such as rituximab, methotrexate, azathioprine, leflunomide, or mycophenolate mofetil are used. Treatments may include NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, and methotrexate. Triple therapy consisting of methotrexate, sulfasalazine and hydroxychloroquine may also effectively control disease activity. Other regimens include dose dense MVAC (DDMVC) and cisplatin, methotrexate and vinblastine (CMV). Methotrexate and corticosteroids are proposed treatments. Standard prophylaxis involves the use of cyclosporine for six months with methotrexate. Probenecid inhibits methotrexate excretion, which increases the risk of methotrexate toxicity. No interaction was found in rheumatoid arthritis patients taking methotrexate. The treatment for scleroderma often includes known teratogens such as cyclophosphamide, methotrexate, mycophenolate, etc. Another common treatment is cyclophosphamide, methotrexate, and fluorouracil (or "CMF"). Biologic monotherapy or tofacitinib with methotrexate may improve ACR50, RA remission rates and function. Methotrexate and vincristine have also been used. The skin tightness may be treated systemically with methotrexate and ciclosporin.